Key facts
- It has raised $63.9M; the latest was Seed Round ($12.9M) in Jul 2024.
- Notable investors include High-Tech Gründerfonds, Novo Holdings, Denmark's Export and Investment Fund, Nordic Mentor Network For Entrepreneurship, Gilde Healthcare — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Draupnir Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Draupnir Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Draupnir Bio
Developer of a cholesterol-lowering medicine designed to prevent blood clots in the heart more effectively than the current medicine. The company's platform technology enables the development of protein degraders that target extracellular disease proteins, with the potential to target the human proteome and offer broad disease applicability across multiple areas of unmet therapeutic need, enabling medical staff to provide a more convenient and accessible treatment option for patients compared to traditional injectable therapies.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2017
- Employees
- 14
- Website
- draupnir.bio/
- Ownership
- Privately Held (backing)
Draupnir Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Draupnir Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Draupnir Bio in its N-PORT filings yet. We sweep new filings monthly.